Strategic Divestitures and Large Expected Cash Proceeds
Signed definitive agreements to sell acute care, interventional urology, and OEM businesses for total cash proceeds of $2.03 billion and expected net after-tax proceeds of approximately $1.8 billion; company intends to use proceeds to repurchase up to $1.0 billion of common stock and pay down roughly $800 million of debt to enhance financial flexibility.
2025 Adjusted EPS Growth
2025 adjusted EPS of $6.98, an 8.7% increase year over year, driven by higher revenue, adjusted operating income (including the vascular intervention acquisition), a lower tax rate and reduced share count, partially offset by higher interest expense and foreign exchange.
Topline Growth and Go-Forward Revenue Guidance
RemainCo delivered pro forma adjusted constant currency revenue growth of 4.7% in 2025; management guided 2026 pro forma adjusted constant currency revenue growth of 4.5% to 5.5%, supporting a mid-single-digit growth profile going forward.
Planned R&D Step-Up to Support Innovation
Teleflex expects RemainCo R&D spend of approximately 8% of sales (versus ~5% historically for Teleflex), signaling a material increase in investment to support product innovation in Interventional and Vascular businesses.
Balance Sheet and Liquidity Improvement
Cash, cash equivalents and restricted cash at year-end 2025 were $402.7 million versus $285.3 million at year-end 2024 (approximately +41%), and management expects to receive ~$1.8 billion in after-tax proceeds upon closings to further strengthen liquidity and enable capital returns.
Planned Cost Actions and Future Margin Upside
Board-approved restructuring expected to realize approximately $50 million in annual pretax savings (substantially completed by mid-2028); management estimates steady-state adjusted operating margin of ~23% once transition service (TS) and manufacturing service (MS) agreements fully offset stranded costs, implying meaningful margin expansion vs. 2026 guidance.